
Omnitrope® in Italian Adults: Safety and Efficacy for Growth Hormone Deficiency
Reading Time: 4 minutes A recent report highlights interim findings in assessing the safety and effectiveness of Omnitrope® in adults aged 30 years or above lacking growth hormone. The "Italian Interim Snapshot" report aims to understand the ongoing safety and effectiveness of Omnitrope®, a recombinant growth hormone identical to Genotropin®, among Italian adults participating in the PATRO Adults study suffering from growth hormone deficiency (GHD). Methods The PATRO Adults study is a long-term observational non-interventional international post-marketing research project in many European nations. The primary objective is to understand long-term safety, while the secondary objective is to focus on the effectiveness of Omnitrope®. The...